Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the REALISTIC phase IIIb study

Michael E. Weinblatt, Roy Fleischmann, Tom W J Huizinga, Paul Emery, Janet Pope, Elena M. Massarotti, Ronald F. van vollenhoven, Jürgen Wollenhaupt, Clifton Bingham, Ben Duncan, Niti Goel, Owen R. Davies, Maxime Dougados

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. Methods: In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy stratified by previous TNF inhibitor use, concomitant methotrexate use and disease duration (

Original languageEnglish (US)
Article numberkes150
Pages (from-to)2204-2214
Number of pages11
JournalRheumatology
Volume51
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Rheumatoid Arthritis
Safety
Antirheumatic Agents
Methotrexate
Population
Placebos
Certolizumab Pegol
Therapeutics

Keywords

  • Biologicals
  • Rheumatoid arthritis
  • Tumour necrosis factor

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Weinblatt, M. E., Fleischmann, R., Huizinga, T. W. J., Emery, P., Pope, J., Massarotti, E. M., ... Dougados, M. (2012). Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the REALISTIC phase IIIb study. Rheumatology, 51(12), 2204-2214. [kes150]. https://doi.org/10.1093/rheumatology/kes150

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis : Results from the REALISTIC phase IIIb study. / Weinblatt, Michael E.; Fleischmann, Roy; Huizinga, Tom W J; Emery, Paul; Pope, Janet; Massarotti, Elena M.; van vollenhoven, Ronald F.; Wollenhaupt, Jürgen; Bingham, Clifton; Duncan, Ben; Goel, Niti; Davies, Owen R.; Dougados, Maxime.

In: Rheumatology, Vol. 51, No. 12, kes150, 12.2012, p. 2204-2214.

Research output: Contribution to journalArticle

Weinblatt, ME, Fleischmann, R, Huizinga, TWJ, Emery, P, Pope, J, Massarotti, EM, van vollenhoven, RF, Wollenhaupt, J, Bingham, C, Duncan, B, Goel, N, Davies, OR & Dougados, M 2012, 'Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the REALISTIC phase IIIb study', Rheumatology, vol. 51, no. 12, kes150, pp. 2204-2214. https://doi.org/10.1093/rheumatology/kes150
Weinblatt, Michael E. ; Fleischmann, Roy ; Huizinga, Tom W J ; Emery, Paul ; Pope, Janet ; Massarotti, Elena M. ; van vollenhoven, Ronald F. ; Wollenhaupt, Jürgen ; Bingham, Clifton ; Duncan, Ben ; Goel, Niti ; Davies, Owen R. ; Dougados, Maxime. / Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis : Results from the REALISTIC phase IIIb study. In: Rheumatology. 2012 ; Vol. 51, No. 12. pp. 2204-2214.
@article{a413246ce0a14383bae90e163308abc8,
title = "Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the REALISTIC phase IIIb study",
abstract = "Objective: To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. Methods: In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy stratified by previous TNF inhibitor use, concomitant methotrexate use and disease duration (",
keywords = "Biologicals, Rheumatoid arthritis, Tumour necrosis factor",
author = "Weinblatt, {Michael E.} and Roy Fleischmann and Huizinga, {Tom W J} and Paul Emery and Janet Pope and Massarotti, {Elena M.} and {van vollenhoven}, {Ronald F.} and J{\"u}rgen Wollenhaupt and Clifton Bingham and Ben Duncan and Niti Goel and Davies, {Owen R.} and Maxime Dougados",
year = "2012",
month = "12",
doi = "10.1093/rheumatology/kes150",
language = "English (US)",
volume = "51",
pages = "2204--2214",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis

T2 - Results from the REALISTIC phase IIIb study

AU - Weinblatt, Michael E.

AU - Fleischmann, Roy

AU - Huizinga, Tom W J

AU - Emery, Paul

AU - Pope, Janet

AU - Massarotti, Elena M.

AU - van vollenhoven, Ronald F.

AU - Wollenhaupt, Jürgen

AU - Bingham, Clifton

AU - Duncan, Ben

AU - Goel, Niti

AU - Davies, Owen R.

AU - Dougados, Maxime

PY - 2012/12

Y1 - 2012/12

N2 - Objective: To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. Methods: In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy stratified by previous TNF inhibitor use, concomitant methotrexate use and disease duration (

AB - Objective: To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. Methods: In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy stratified by previous TNF inhibitor use, concomitant methotrexate use and disease duration (

KW - Biologicals

KW - Rheumatoid arthritis

KW - Tumour necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=84870317631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870317631&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kes150

DO - 10.1093/rheumatology/kes150

M3 - Article

C2 - 22923753

AN - SCOPUS:84870317631

VL - 51

SP - 2204

EP - 2214

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 12

M1 - kes150

ER -